Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka
The company received gross proceeds of approximately US$1.7 million and net proceeds,
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
Sirius JV will be owned 51% by Sirius and 49% by Adani
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Innovent will supply sintilimab for the collaborated clinical trial
Ecolab’s continued leadership position on renowned sustainability indices demonstrates the company’s record of advancing sustainable growth
Subscribe To Our Newsletter & Stay Updated
